Conditions
Small Cell Lung Cancer
Trial Purpose
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
NATIONAL TRIAL REFERENCE NUMBER
NCT04624204
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Study
All patients who enroll in the trial will receive medication while on the study.
33% of patients will receive pembrolizumab (pembro) along with chemotherapy* and radiation followed by pembro and olaparib placebo
33% of patients will receive pembro along with chemotherapy* and radiation followed by pembro and olaparib
33% of patients will receive pembro placebo along with chemotherapy* and radiation followed by pembro placebo and olaparib placebo
*Your doctor will decide which chemotherapy treatment (cisplatin with etoposide or carboplatin with etoposide) is best for you.
Trial Phase
Trial Phase 3
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Actual study start date December 8, 2020
- Estimated primary completion date October 28, 2027
- Estimated study completion date October 28, 2027
Trial Locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about